

### Ixempra® (Ixabepilone) Prior Authorization Form

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_

#### Drug Information

Physician billing (HCPCS code: \_\_\_\_\_) Start Date (or date of next dose): \_\_\_\_\_

Dose: \_\_\_\_\_ Dosing Regimen: \_\_\_\_\_

#### Billing Provider Information

Provider NPI: \_\_\_\_\_ Provider Name: \_\_\_\_\_

Provider Phone: \_\_\_\_\_ Provider Fax: \_\_\_\_\_

#### Prescriber Information

Prescriber NPI: \_\_\_\_\_ Prescriber Name: \_\_\_\_\_

Prescriber Phone: \_\_\_\_\_ Prescriber Fax: \_\_\_\_\_ Specialty: \_\_\_\_\_

#### Criteria

##### For Initial Authorization:

##### 1. Please indicate the diagnosis and information

**Breast Cancer**

- A. Is disease metastatic or locally advanced? Yes \_\_\_ No \_\_\_
- B. Will ixabepilone be used in combination with capecitabine? Yes \_\_\_ No \_\_\_
  - i. Has member failed an anthracycline and a taxane? Yes \_\_\_ No \_\_\_
  - ii. Is anthracycline contraindicated? Yes \_\_\_ No \_\_\_
- C. Will ixabepilone be used as a single agent? Yes \_\_\_ No \_\_\_
  - i. Has member failed capecitabine, an anthracycline, and a taxane? Yes \_\_\_ No \_\_\_
  - ii. Has member responded to preoperative systemic therapy? Yes \_\_\_ No \_\_\_
  - iii. Has member received at least 1 line of therapy for recurrent unresectable (local or regional) disease? Yes \_\_\_ No \_\_\_
  - iv. Is disease human epidermal growth factor receptor 2 (HER2)-negative? Yes \_\_\_ No \_\_\_
- D. Will ixabepilone be used in combination with trastuzumab? Yes \_\_\_ No \_\_\_
  - i. Is disease HER2-positive? Yes \_\_\_ No \_\_\_
  - ii. Will ixabepilone be used as third-line or subsequent therapy? Yes \_\_\_ No \_\_\_

**If diagnosis is not listed above, please indicate diagnosis:** \_\_\_\_\_

Additional Information: \_\_\_\_\_

##### For Continued Authorization:

- 1. Does member have any evidence of progressive disease while on ixabepilone?  
Yes \_\_\_ No \_\_\_
- 2. Has the member experienced any adverse drug reactions related to ixabepilone therapy?  
Yes \_\_\_ No \_\_\_

If yes, please specify adverse reactions: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

*I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Failure to complete this form in full will result in processing delays.*

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy  
Pharmacy Management Consultants  
Product Based Prior Authorization Unit

Fax: 1-800-224-4014  
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*